Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development

Appointment:
Pfizer has appointed Dr. Chris Boshoff as Chief Scientific Officer and President, Research & Development, effective January 1, 202512.

Succession:
Dr. Boshoff succeeds Dr. Mikael Dolsten, whose departure was announced earlier this year12.

Background:
Dr. Boshoff previously served as Chief Oncology Officer and Executive Vice President at Pfizer, delivering 24 approved innovative medicines and biosimilars across 30+ indications during his 11-year tenure2.

Oncology Structure:
Pfizer’s Oncology R&D organization will maintain its fully integrated structure, with Roger Dansey serving as Interim Chief Oncology Officer and reporting to Dr. Boshoff12.

New Hires:
Johanna Bendell, M.D., will join Pfizer from Roche in 2025 as Chief Development Officer, Oncology, succeeding Roger Dansey’s responsibilities13.

Leadership Vision:
Dr. Boshoff aims to propel Pfizer’s R&D engine forward, focusing on delivering impactful breakthrough medicines with blockbuster potential12.

Sources:

1. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-new-chief-scientific-officer-and-president

2. https://www.stocktitan.net/news/PFE/pfizer-announces-new-chief-scientific-officer-and-president-research-nkedwcs0pt76.html

3. https://www.fiercebiotech.com/biotech/pfizer-plucks-internal-candidate-replace-rd-head-dolsten-triggering-series-leadership